Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2017-02 open-label extension of cenobamate in Japanese adults with partial-onset seizures
jRCT2031220198Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cenobamate in epilepsy, sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability. Started Nov 2022; status: recruiting.
02
Drugs
cenobamate
03
Conditions
epilepsy
Beyond the preview
Go deeper on jRCT2031220198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220198.